- Achillion Pharmaceuticals (ACHN) gives an HCV pipeline update.
- Sovaprevir is still on clinical hold even though the company says it has "addressed all issues noted in the FDA's June 29, 2013 letter." (previous)
- As for the sovaprevir/ACH-3102/ribavirin combo, rapid virologic response was 79%. That doesn't appear to stack up too well with results from BMY, GILD, and ABBV if one assumes RVR is a good indicator of SVR. (more on this here)
- Additionally, the company indicates it will advance ACH-2684 into Phase 2 combo studies. (PR)
- ACHN -44% AH